Loading...

VentriPoint Diagnostics

DB:5V7
Snowflake Description

Worrying balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
5V7
DB
CA$8M
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

Ventripoint Diagnostics Ltd., a medical device company, develops and commercializes diagnostic tools that monitor patients with heart disease primarily in Canada, the Unites States, and China. The last earnings update was 145 days ago. More info.


Add to Portfolio Compare Print
  • VentriPoint Diagnostics has significant price volatility in the past 3 months.
5V7 Share Price and Events
7 Day Returns
-9.3%
DB:5V7
-1.8%
DE Medical Equipment
1%
DE Market
1 Year Returns
-60.5%
DB:5V7
21.3%
DE Medical Equipment
-5.6%
DE Market
5V7 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
VentriPoint Diagnostics (5V7) -9.3% -30.6% -22.7% -60.5% - -
DE Medical Equipment -1.8% 2.1% 8.6% 21.3% 90.2% 197.1%
DE Market 1% 6.1% 8.4% -5.6% 10.9% 13.8%
1 Year Return vs Industry and Market
  • 5V7 underperformed the Medical Equipment industry which returned 21.3% over the past year.
  • 5V7 underperformed the Market in Germany which returned -5.6% over the past year.
Price Volatility
5V7
Industry
5yr Volatility vs Market

5V7 Value

 Is VentriPoint Diagnostics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether VentriPoint Diagnostics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as VentriPoint Diagnostics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for VentriPoint Diagnostics. This is due to cash flow or dividend data being unavailable. The share price is €0.068.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for VentriPoint Diagnostics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are VentriPoint Diagnostics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:5V7 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-09-30) in CAD CA$-0.05
TSXV:VPT Share Price ** TSXV (2019-04-24) in CAD CA$0.13
Germany Medical Equipment Industry PE Ratio Median Figure of 9 Publicly-Listed Medical Equipment Companies 31.46x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.72x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of VentriPoint Diagnostics.

DB:5V7 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSXV:VPT Share Price ÷ EPS (both in CAD)

= 0.13 ÷ -0.05

-2.43x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • VentriPoint Diagnostics is loss making, we can't compare its value to the DE Medical Equipment industry average.
  • VentriPoint Diagnostics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does VentriPoint Diagnostics's expected growth come at a high price?
Raw Data
DB:5V7 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.43x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Germany Medical Equipment Industry PEG Ratio Median Figure of 6 Publicly-Listed Medical Equipment Companies 2.65x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for VentriPoint Diagnostics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on VentriPoint Diagnostics's assets?
Raw Data
DB:5V7 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-09-30) in CAD CA$0.00
TSXV:VPT Share Price * TSXV (2019-04-24) in CAD CA$0.13
Germany Medical Equipment Industry PB Ratio Median Figure of 13 Publicly-Listed Medical Equipment Companies 4.23x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:5V7 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSXV:VPT Share Price ÷ Book Value per Share (both in CAD)

= 0.13 ÷ 0.00

-46.12x

* Primary Listing of VentriPoint Diagnostics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • VentriPoint Diagnostics has negative assets, we can't compare the value of its assets to the DE Medical Equipment industry average.

Next steps:

  1. Take a look at our analysis of 5V7’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through VentriPoint Diagnostics's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Medical Equipment industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess VentriPoint Diagnostics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. VentriPoint Diagnostics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

5V7 Future Performance

 How is VentriPoint Diagnostics expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as VentriPoint Diagnostics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
11.9%
Expected Medical Equipment industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is VentriPoint Diagnostics expected to grow at an attractive rate?
  • Unable to compare VentriPoint Diagnostics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare VentriPoint Diagnostics's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare VentriPoint Diagnostics's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:5V7 Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 11.9%
Germany Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 6.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:5V7 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:5V7 Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2018-09-30 0 -3 -3
2018-06-30 0 -3 -3
2018-03-31 0 -3 0
2017-12-31 0 -3 -4
2017-09-30 0 -3 -2
2017-06-30 0 -2 -3
2017-03-31 0 -2 -6
2016-12-31 0 -2 -3
2016-09-30 0 -2 -2
2016-06-30 0 -2 -2
2016-03-31 0 -2 -2
2015-12-31 0 -1 -2

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if VentriPoint Diagnostics is high growth as no earnings estimate data is available.
  • Unable to determine if VentriPoint Diagnostics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:5V7 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from VentriPoint Diagnostics Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:5V7 Past Financials Data
Date (Data in CAD Millions) EPS *
2018-09-30 -0.05
2018-06-30 -0.05
2018-03-31 0.00
2017-12-31 -0.08
2017-09-30 -0.05
2017-06-30 -0.09
2017-03-31 -0.20
2016-12-31 -0.10
2016-09-30 -0.09
2016-06-30 -0.09
2016-03-31 -0.08
2015-12-31 -0.08

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if VentriPoint Diagnostics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of 5V7’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. VentriPoint Diagnostics's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  3. VentriPoint Diagnostics's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess VentriPoint Diagnostics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
VentriPoint Diagnostics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

5V7 Past Performance

  How has VentriPoint Diagnostics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare VentriPoint Diagnostics's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • VentriPoint Diagnostics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare VentriPoint Diagnostics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare VentriPoint Diagnostics's 1-year growth to the DE Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
VentriPoint Diagnostics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from VentriPoint Diagnostics Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:5V7 Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-09-30 0.06 -2.86 2.43 1.44
2018-06-30 0.00 -2.56 2.74 1.47
2018-03-31 0.00 0.21 2.44 1.33
2017-12-31 0.04 -3.70 2.21 1.18
2017-09-30 0.24 -2.17 1.82 1.02
2017-06-30 0.24 -3.08 1.17 0.87
2017-03-31 0.25 -5.90 0.96 1.03
2016-12-31 0.21 -2.62 0.88 1.16
2016-09-30 0.01 -2.46 0.90 1.26
2016-06-30 0.02 -2.28 0.96 1.10
2016-03-31 0.05 -1.94 1.12 0.84
2015-12-31 0.05 -1.77 1.17 0.67
2015-09-30 0.10 -1.89 1.42 0.48
2015-06-30 0.15 -1.98 1.70 0.49
2015-03-31 0.12 -2.38 1.62 0.52
2014-12-31 0.13 -2.18 1.35 0.52
2014-09-30 0.04 -0.76 1.34 0.61
2014-06-30 0.08 -1.81 1.26 0.89
2014-03-31 0.08 -1.74 1.39 1.20
2013-12-31 0.07 -1.65 1.51 1.57
2013-09-30 0.11 -3.58 1.62 2.20
2013-06-30 0.18 -2.94 1.68 2.73
2013-03-31 0.38 -3.64 2.00 2.92
2012-12-31 0.37 -4.03 2.29 2.92
2012-09-30 0.43 -3.14 2.23 2.61
2012-06-30 0.38 -4.12 2.54 2.32

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if VentriPoint Diagnostics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if VentriPoint Diagnostics has efficiently used its assets last year compared to the DE Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if VentriPoint Diagnostics improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess VentriPoint Diagnostics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
VentriPoint Diagnostics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

5V7 Health

 How is VentriPoint Diagnostics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up VentriPoint Diagnostics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • VentriPoint Diagnostics's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • VentriPoint Diagnostics has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of VentriPoint Diagnostics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • VentriPoint Diagnostics has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from VentriPoint Diagnostics Company Filings, last reported 6 months ago.

DB:5V7 Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-09-30 -0.17 0.00 0.65
2018-06-30 -1.19 0.00 0.55
2018-03-31 -1.17 0.00 0.93
2017-12-31 -1.63 0.00 1.36
2017-09-30 -0.17 0.00 2.27
2017-06-30 -0.79 0.00 3.01
2017-03-31 -3.49 0.00 3.39
2016-12-31 -2.25 0.60 0.19
2016-09-30 -1.90 0.71 0.18
2016-06-30 -1.38 0.65 0.42
2016-03-31 -0.66 0.54 0.98
2015-12-31 -0.27 0.60 1.98
2015-09-30 -0.64 0.66 2.39
2015-06-30 -2.86 1.18 0.39
2015-03-31 -2.90 1.06 0.11
2014-12-31 -2.39 0.83 0.17
2014-09-30 -2.17 0.75 0.41
2014-06-30 -2.12 0.90 0.92
2014-03-31 -3.32 2.02 0.14
2013-12-31 -3.11 1.98 0.36
2013-09-30 -4.49 2.22 0.45
2013-06-30 -3.06 1.67 0.28
2013-03-31 -2.57 1.39 0.33
2012-12-31 -2.66 1.36 0.46
2012-09-30 -1.94 1.33 1.39
2012-06-30 -1.21 1.29 2.22
  • VentriPoint Diagnostics has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if VentriPoint Diagnostics's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • VentriPoint Diagnostics has less than a year of cash runway based on current free cash flow.
  • VentriPoint Diagnostics has less than a year of cash runway if free cash flow continues to grow at historical rates of 31.4% each year.
X
Financial health checks
We assess VentriPoint Diagnostics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. VentriPoint Diagnostics has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

5V7 Dividends

 What is VentriPoint Diagnostics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from VentriPoint Diagnostics dividends.
If you bought €2,000 of VentriPoint Diagnostics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate VentriPoint Diagnostics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate VentriPoint Diagnostics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:5V7 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Germany Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 8 Stocks 1.4%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as VentriPoint Diagnostics has not reported any payouts.
  • Unable to verify if VentriPoint Diagnostics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of VentriPoint Diagnostics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as VentriPoint Diagnostics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess VentriPoint Diagnostics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can VentriPoint Diagnostics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. VentriPoint Diagnostics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

5V7 Management

 What is the CEO of VentriPoint Diagnostics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
George Adams
COMPENSATION CA$369,795
AGE 67
TENURE AS CEO 8.5 years
CEO Bio

Dr. George Adams, B.A.Sc., M.A.Sc., Ph.D., ICD.D., has been the Chief Executive Officer of VentriPoint Diagnostics Ltd. since October 1, 2010 and served as its President from October 1, 2010 to December 2017. Dr. Adams has been the President of Hemo-Stat Ltd since 1989. He is a Director of Cell MedX Corp. since March 2018. He served as the President and Chief Executive Officer of Amorfix Life Sciences Ltd. from April 1, 2005 to June 3, 2010 and as an Executive Director from September 24, 2005 to June 3, 2010. Dr. Adams served as President and Chief Executive Officer of the University of Toronto Innovations Foundation from 1999 to October 2004, where he was involved in creating companies and commercializing technologies. He served as President of the Canadian Biomaterials Society and Corvits. He served as the President of Corvita from 1994 to 1996. He served as a Senior Scientist of the Canadian Red Cross Blood Transfusion Service until 1980. Dr. Adams served as an Associate Professor of Biochemistry and Surgery at University of Ottawa. He served as the Chairman of Sernova Corp. from May 3, 2007 to March 2015. Dr. Adams has also been a Director of 8 start-up companies. He has been a Director of VentriPoint Diagnostics Ltd. since October 1, 2010. He serves as a Member of Advisory Board of Roadmap Capital Inc. He served as Director of Sernova Corp. until April 28, 2015 and previously also served as its Director since September 25, 2006. Dr. Adams served as Director of Artificial Heart Development Program. He served as a Member of Scientific Advisory Board at Resverlogix Corp. since May 2006. Dr. Adams is an expert in thrombosis and Vascular biology, has partnered with Baxter Heathcare, World Heart, Dupont, Corvita, Pfizer and Boston Scientific over 30 years to develop and commercialize medical devices. He has 124 publications including 9 invited reviews, 26 full papers and 3 patents. Dr. Adams is a reviewer for numerous scientific journals, national granting agencies and several national and provincial Centers of Excellence. He has an extensive history of combining science and entrepreneurial ventures. Dr. Adams obtained his PhD. in Medical Sciences from McMaster University. He received his B.A.S.C and an M.A.S.C. in Mechanical Engineering from the University of Waterloo. Dr. Adams has a postdoctoral year in Vascular Biology at the Bayor College of Medicine.

CEO Compensation
  • George's compensation has increased whilst company is loss making.
  • George's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the VentriPoint Diagnostics management team in years:

1.3
Average Tenure
  • The average tenure for the VentriPoint Diagnostics management team is less than 2 years, this suggests a new team.
Management Team

George Adams

TITLE
CEO & Director
COMPENSATION
CA$370K
AGE
67
TENURE
8.5 yrs

Desmond Hirson

TITLE
President
COMPENSATION
CA$294K
TENURE
1.3 yrs

Ellen Briant

TITLE
CFO & Corporate Secretary
COMPENSATION
CA$216K
TENURE
6.2 yrs

Alvira Macanovic

TITLE
Vice President of Development & Operations
TENURE
1.3 yrs

Jessica Naman

TITLE
Marketing Manager
TENURE
0.5 yrs

Jim Graba

TITLE
Application Specialist & Chief Trainer
TENURE
0.9 yrs
Board of Directors Tenure

Average tenure of the VentriPoint Diagnostics board of directors in years:

7.1
Average Tenure
  • The tenure for the VentriPoint Diagnostics board of directors is about average.
Board of Directors

George Adams

TITLE
CEO & Director
COMPENSATION
CA$370K
AGE
67
TENURE
8.5 yrs

Danny Dalla-Longa

TITLE
Director
COMPENSATION
CA$41K
AGE
64
TENURE
13.9 yrs

Sam Schwartz

TITLE
Chair of Business Advisory Committee
TENURE
1.1 yrs

David Sahn

TITLE
Member of Scientific Advisory Board

Mark Lewin

TITLE
Member of Scientific Advisory Board

Michael Gatzoulis

TITLE
Member of Scientific Advisory Board

Richard Krasuski

TITLE
Member of Scientific Advisory Board
TENURE
7.9 yrs

Scott Solomon

TITLE
Member of Scientific Advisory Board
TENURE
7.1 yrs

Alan Rabinowitz

TITLE
Director
COMPENSATION
CA$40K
TENURE
3.3 yrs

David Willis

TITLE
Director
COMPENSATION
CA$46K
TENURE
3.4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
21. Jan 19 Sell George Adams Individual 17. Jan 19 17. Jan 19 -1,500,000 €0.10 €-153,638
X
Management checks
We assess VentriPoint Diagnostics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. VentriPoint Diagnostics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

5V7 News

Simply Wall St News

5V7 Company Info

Description

Ventripoint Diagnostics Ltd., a medical device company, develops and commercializes diagnostic tools that monitor patients with heart disease primarily in Canada, the Unites States, and China. The company offers Ventripoint Medical System, medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient’s heart chambers. It also provides a suite of applications for various heart diseases and imaging modalities, including congenital heart diseases, left or right heart failure, and normal hearts. The company was incorporated in 2005 and is headquartered in Toronto, Canada.

Details
Name: VentriPoint Diagnostics Ltd.
5V7
Exchange: DB
Founded: 2005
CA$5,209,604
60,525,238
Website: http://www.ventripoint.com
Address: VentriPoint Diagnostics Ltd.
2 Sheppard Avenue East,
Suite 605,
Toronto,
Ontario, M2N 5Y7,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSXV VPT Common Shares TSX Venture Exchange CA CAD 19. Sep 2007
OTCPK VPTD.F Common Shares Pink Sheets LLC US USD 19. Sep 2007
DB 5V7 Common Shares Deutsche Boerse AG DE EUR 19. Sep 2007
Number of employees
Current staff
Staff numbers
0
VentriPoint Diagnostics employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/24 23:18
End of day share price update: 2019/04/24 00:00
Last earnings filing: 2018/11/30
Last earnings reported: 2018/09/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.